Eastgate Biotech, founded in 2005 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company specializing in the discovery and development of novel therapeutics for oncology and autoimmune diseases. The company’s research platform leverages proprietary antibody engineering and small molecule screening technologies to identify candidates that modulate immune pathways. Eastgate Biotech operates as a publicly traded entity, listing its shares on the OTC Markets under the ticker ETBI.
At the core of Eastgate’s operations is a robust pipeline of targeted therapies designed to address high‐unmet medical needs. Lead programs include an antibody-drug conjugate for solid tumors, a selective kinase inhibitor for hematologic cancers, and a biologic candidate aimed at regulating overactive immune responses in conditions such as rheumatoid arthritis and psoriasis. These programs have progressed through preclinical validation, with several poised to enter Phase I and Phase II clinical trials.
Eastgate Biotech maintains research facilities in Massachusetts and strategic partnerships with academic centers in Europe and Asia to facilitate global development efforts. The company has also forged collaborations with contract research organizations (CROs) to accelerate toxicology studies and manufacturing scale-up. Through these alliances, Eastgate seeks to broaden its geographic reach and access diverse patient populations in North America, Europe and Asia-Pacific regions.
The leadership team is led by CEO Dr. Marianne Liu, a veteran biopharmaceutical executive with over 20 years of experience in drug development and commercialization. Chief Scientific Officer Dr. Alejandro Reyes oversees research strategy, drawing on his background in immunology and molecular biology. The board of directors comprises industry experts and seasoned investors who provide governance and strategic guidance as Eastgate Biotech advances its mission of bringing transformative treatments to patients worldwide.
AI Generated. May Contain Errors.
